Curis, Inc. (CRIS) Receives $24.33 Consensus Target Price from Analysts
Shares of Curis, Inc. (NASDAQ:CRIS) have received a consensus rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $24.33.
CRIS has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Curis from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. ValuEngine raised Curis from a “sell” rating to a “hold” rating in a research report on Thursday, May 31st. Cowen reaffirmed a “buy” rating on shares of Curis in a research report on Monday, August 6th. Finally, SunTrust Banks cut their target price on Curis to $8.00 and set a “buy” rating on the stock in a research report on Friday, August 3rd.
Institutional investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in shares of Curis during the second quarter valued at $540,000. Paloma Partners Management Co purchased a new position in shares of Curis during the second quarter valued at $223,000. LMR Partners LLP purchased a new position in shares of Curis during the second quarter valued at $124,000. Sio Capital Management LLC purchased a new position in shares of Curis during the first quarter valued at $545,000. Finally, Arnhold LLC purchased a new position in shares of Curis during the first quarter valued at $1,907,000. 33.49% of the stock is currently owned by institutional investors.
Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. The company had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.41 million. Curis had a negative return on equity of 225.77% and a negative net margin of 407.29%. research analysts forecast that Curis will post -1.18 EPS for the current year.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Featured Story: Stock Symbols and CUSIP Explained
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.